Connection

Michael Hallek to Drug Administration Schedule

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Drug Administration Schedule.
Michael Hallek
Connection Strength
0.192
Drug Administration Schedule
  1. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
    View in: PubMed
    Score: 0.110
  2. [Elderly patients in clinical trials: new fitness-adapted concepts]. Internist (Berl). 2007 Nov; 48(11):1232-7.
    View in: PubMed
    Score: 0.052
  3. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.